Miniatura

Fitxers

563902.pdf (222.09 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2007

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/22445

Outcomes from studies of Antineutrophil Cytoplasm Antibody Associated Vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1136/ard.2007.071936

Resum

Objectives: We undertook a systematic literature review as a background to the European League Against Rheumatism (EULAR) recommendations for conducting clinical trials in anti-neutrophil cytoplasm antibody associated vasculitis (AAV), and to assess the quality of evidence for outcome measures in AAV. Methods: Using a systematic Medline search, we categorised the identified studies according to diagnoses. Factors affecting remission, relapse, renal function and overall survival were identified. Results: A total of 44 papers were reviewed from 502 identified by our search criteria. There was considerable inconsistency in definitions of end points. Remission rates varied from 30% to 93% in Wegener granulomatosis (WG), 75% to 89% in microscopic polyangiitis (MPA) and 81% to 91% in Churg¿Strauss syndrome (CSS). The 5-year survival for WG, MPA and CSS was 74¿91%, 45¿76% and 60¿97%. Relapse (variably defined) was common in the first 2 years but the frequency varied: 18% to 60% in WG, 8% in MPA, and 35% in CSS. The rate of renal survival in WG varied from 23% at 15 months to 23% at 120 months. Methods used to assess morbidity varied between studies. Ignoring the variations in definitions of the stage of disease, factors influencing remission, relapse, renal and overall survival included immunosuppressive therapy used, type of organ involvement, presence of ANCA, older age and male ender. Conclusions: Factors influencing remission, relapse, renal and overall survival include the type of immunosuppressive therapy used, pattern of organ involvement, presence of ANCA, older age and male gender. Methodological variations between studies highlight the need for a consensus on terminology and definitions for future conduct of clinical studies in AAV.

Matèries

Vasculitis, Autoanticossos

Matèries (anglès)

Vasculitis, Autoantibodies

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

MUKHTYAR, C., FLOSSMANN, O., HELLMICH, B., BACON, Paul a., CID XUTGLÀ, M. cinta, COHEN TERVAERT, J. w., GROSS, W. l., GUILLEVIN, Loïc, JAYNE, David, MAHR, A., MERKEL, Peter a., RASPE, H., SCOTT, D. g. i., WITTER, J., YAZICI, H., LUQMANI, R. a.. Outcomes from studies of Antineutrophil Cytoplasm Antibody Associated Vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.. _Annals of the Rheumatic Diseases_. 2008. Vol. 67, núm. 7, pàgs. 1004-1010. [consulta: 24 de gener de 2026]. ISSN: 0003-4967. [Disponible a: https://hdl.handle.net/2445/22445]

Exportar metadades

JSON - METS

Compartir registre